to experience the full functionality of mail.com.
Enhanced by Google
Gilead Sciences Inc
July 29, 2016
Merck posts strong 2Q numbers, while building for long term
Drugmaker Merck & Co., focused heavily on its long-term future as it builds sales of crucial new medicines Keytruda for ...
June 28, 2016
FDA approves first pill to treat all forms of hepatitis C
Federal health officials on Tuesday approved the first pill to treat all major forms of hepatitis C, the latest in a series ...
May 05, 2016
Merck beats 1Q profit views with tight cost controls
Merck posted an 18 percent jump in first-quarter income, beating Wall Street expectations, as reduced spending on marketing, ...
April 19, 2016
Johnson & Johnson rides strong prescription sales in 1Q
Johnson & Johnson beat Wall Street expectations despite flat first-quarter profit, as higher sales of new prescription drugs ...
April 04, 2016
Gilead paying up to $1.2B for Nimbus unit, drug candidate
Biologic drugmaker Gilead Sciences Inc. said Monday that it will buy a subsidiary of Nimbus Therapeutics LLC and its ...
March 25, 2016
Jury: Gilead owes Merck $200M in damages over drug patents
The federal jury in a patent trial has ordered drugmaker Gilead Sciences to pay Merck $200 million in damages for infringing ...
March 22, 2016
Jury finds for Merck in hepatitis drug fight with Gilead
A federal jury in California has ruled in favor of drugmaker Merck & Co. in a high-stakes lawsuit against rival Gilead ...